Klisyri (Tirbanibulin)

Tirbanibulin blocks tubulin polymerization and inhibits Src kinase signaling within abnormal keratinocytes. This dual action stops cell division and induces programmed cell death, leading to the removal of dysplastic skin cells that characterize actinic keratosis.

The dosing regimen for Klisyri is determined by the prescribing healthcare professional. Typically, the gel is applied once daily to the affected area for a prescribed number of days, but the exact amount and duration should follow the prescriber’s instructions.

Safety data for tirbanibulin in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, so it should be avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To request Klisyri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Klisyri’s tirbanibulin offers a distinct mechanism—kinase inhibition—compared with alternatives such as 5‑fluorouracil or imiquimod, which act as antimetabolites or immune modulators. Clinical data suggest comparable lesion clearance rates, with a short treatment course and a different side‑effect profile.

Klisyri should be stored at room temperature, below 25 °C, in its original packaging. Protect the gel from moisture and direct sunlight. Keep the container tightly closed when not in use to maintain product stability.

Klisyri is applied topically to the affected skin area. The prescriber will indicate the amount to use, usually a thin layer covering the lesion, and the frequency—commonly once daily—for the prescribed treatment period.

Serious risks include severe allergic reactions such as anaphylaxis, extensive ulceration of the treated skin, and secondary bacterial infection. Patients should seek immediate medical attention if they experience widespread rash, difficulty breathing, or signs of infection.

Klisyri is contraindicated in individuals with known hypersensitivity to tirbanibulin or any component of the formulation. It should also be avoided on broken, inflamed, or infected skin, and in pregnant or breastfeeding women unless the prescriber determines that the benefit outweighs the risk.